Literature DB >> 17470162

Change in International Prostate Symptom Score, prostrate-specific antigen and prostate volume in patients with benign prostatic hyperplasia followed longitudinally.

Taiji Tsukamoto1, Naoya Masumori, Mahbubur Rahman, Martin M Crane.   

Abstract

OBJECTIVE: The natural history of benign prostatic hyperplasia (BPH) in Japan resembles Western studies in that symptoms worsen, improve or stabilize in equal proportions of patients. We sought to determine if this pattern persisted in men seeking care at a urology referral center and if worsening of symptoms was due to increase in prostate volume (PV).
METHODS: We reviewed the records of all BPH patients who attended the Urology Clinic of Sapporo Medical University Hospital, during December 2003 and June 2004 with the inclusion criterion that they have at least two PV and lower urinary tract symptoms measurements using the International Prostate Symptom Score (IPSS). Patients who had prostate cancer or who underwent hormone therapy or prostate surgery between the two visits were excluded. Correlation (Spearman's rank) was used to assess interrelationships among variables at baseline and follow up; the strength of association between change in IPSS and change in PV were modeled by multiple linear regression.
RESULTS: Sixty-seven patients were eligible. Baseline PV correlated with residual urine volume (r = 0.37, P < 0.05) and prostate-specific antigen (PSA; r = 0.65, P < 0.001) but not IPSS (r =-0.16). PV increased in 46 (70%) men, remained the same in 10 and decreased in 11; in the former group, the mean prostate enlargement generally increased as baseline PV increased. In multiple linear regression models that included baseline IPSS, correlation between change in IPSS and change in PV was 0.47 (P = 0.05) based on 25 patients with measures at concurrent visits. Change in PV was also correlated with change in quality of life score (0.46, P = 0.02) but not with change in PSA (r = 0.38, P = 0.07, maximum flow rate (-0.24) or residual urine volume (-0.06).
CONCLUSIONS: IPSS were not correlated with any laboratory measure of urinary function at baseline; however, change in IPSS was associated with change in PV. PV was also moderately correlated to PSA levels and residual urine volume at baseline.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17470162     DOI: 10.1111/j.1442-2042.2007.01596.x

Source DB:  PubMed          Journal:  Int J Urol        ISSN: 0919-8172            Impact factor:   3.369


  13 in total

1.  2010 Update: Guidelines for the management of benign prostatic hyperplasia.

Authors:  J Curtis Nickel; Carlos E Méndez-Probst; Thomas F Whelan; Ryan F Paterson; Hassan Razvi
Journal:  Can Urol Assoc J       Date:  2010-10       Impact factor: 1.862

2.  Prostate volume growth rate changes over time: Results from men 18 to 92 years old in a longitudinal community-based study.

Authors:  Si-Hui Li; Qun-Fang Yang; Pei-Yuan Zuo; Yu-Wei Liu; Yu-Hua Liao; Cheng-Yun Liu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2016-12-07

3.  Canadian Urological Association guideline on male lower urinary tract symptoms/benign prostatic hyperplasia (MLUTS/BPH): 2018 update.

Authors:  J Curtis Nickel; Lorne Aaron; Jack Barkin; Dean Elterman; Mahmoud Nachabé; Kevin C Zorn
Journal:  Can Urol Assoc J       Date:  2018-10       Impact factor: 1.862

4.  Effect of prostatitis on lower urinary tract symptoms: retrospective analysis of prostate biopsy tissue.

Authors:  Jai Hyun Chung; Ji Hyeong Yu; Luck Hee Sung; Chung Hee Noh; Jae Yong Chung
Journal:  Korean J Urol       Date:  2012-02-20

Review 5.  Novel drug targets for the pharmacotherapy of benign prostatic hyperplasia (BPH).

Authors:  S Ventura; V l Oliver; C W White; J H Xie; J M Haynes; B Exintaris
Journal:  Br J Pharmacol       Date:  2011-07       Impact factor: 8.739

6.  UPDATE - Canadian Urological Association guideline: Male lower urinary tract symptoms/benign prostatic hyperplasia.

Authors:  Dean Elterman; Mélanie Aubé-Peterkin; Howard Evans; Hazem Elmansy; Malek Meskawi; Kevin C Zorn; Naeem Bhojani
Journal:  Can Urol Assoc J       Date:  2022-08       Impact factor: 2.052

7.  Serum prostate-specific antigen as a predictor of prostate volume and lower urinary tract symptoms in a community-based cohort: a large-scale Korean screening study.

Authors:  Dong Soo Park; Jong Jin Oh; Jae Yup Hong; Young Kwon Hong; Don Kyung Choi; In Hyuck Gong; Jin Ho Hwang; Sung Won Kwon
Journal:  Asian J Androl       Date:  2013-01-28       Impact factor: 3.285

8.  Prostate volume changes over time: results from the Baltimore Longitudinal Study of Aging.

Authors:  Stacy Loeb; Anna Kettermann; H Ballentine Carter; Luigi Ferrucci; E Jeffrey Metter; Patrick C Walsh
Journal:  J Urol       Date:  2009-08-15       Impact factor: 7.450

9.  Establishment of Reference Ranges for Prostate Volume and Annual Prostate Volume Change Rate in Korean Adult Men: Analyses of a Nationwide Screening Population.

Authors:  Jinsung Park; Dong-Gi Lee; Beomseok Suh; Sung Yong Cho; In Ho Chang; Sung Hyun Paick; Hyung-Lae Lee
Journal:  J Korean Med Sci       Date:  2015-07-15       Impact factor: 2.153

10.  Does prostate volume affect the efficacy of α1D/A: Adrenoceptor antagonist naftopidil?

Authors:  Yasushi Tanuma; Yoshinori Tanaka; Ko Takeyama; Tomoshi Okamoto
Journal:  Urol Ann       Date:  2016 Jan-Mar
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.